Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Predicting resistance to targeted therapies in melanoma

Christian Blank • 27 Sep 2019
ESMO 2019
Melanoma Skin Cancer

Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, outlines how we might be able to predict resistance to targeted therapies in melanoma patients. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Christian Blank

1:55
Neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Christian Blank • 16 Apr 2021
1:44
The future of adjuvant therapy in melanoma
Christian Blank • 19 Apr 2021
1:16
Neoadjuvant IPI + NIVO in stage III melanoma: updates from OpACIN & OpACIN-neo
Christian Blank • 19 Apr 2021
1:34
OpACIN and OpACIN-neo trial updates
Christian Blank • 27 Sep 2019

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals